NextGen Genecore Paradigm - PDL1 and HRD
NextGen Genecore Paradigm - PDL1 and HRD** Price
Brief Details
What Is a NextGen GeneCore Paradigm – PDL1 and HRD?
The NextGen GeneCore Paradigm – PDL1 and HRD is an advanced genetic test that combines two critical biomarker analyses using next-generation sequencing technology (NGS). This comprehensive diagnostic panel is performed on tumour tissue samples to provide your oncologist with detailed information about your cancer's characteristics.
The test helps detect specific biological markers that guide treatment decisions for cancer patients, particularly identifying which modern treatments like immunotherapy or targeted therapy will be most effective for your individual case.
What Does the NextGen GeneCore Paradigm – PDL1 and HRD Measure?
The GeneCore Paradigm – PDL1 and HRD provides your oncologist with a detailed molecular profile of your cancer to enable personalised treatment decisions. The test measures:
- Programmed Death-Ligand 1 (PD-L1) Expression: Measures the amount of PD-L1 protein on cancer cells, which helps determine if immunotherapy treatments will be effective.
- Homologous Recombination Deficiency (HRD) Status: Checks if cancer cells have faulty DNA repair mechanisms, indicating vulnerability to PARP inhibitor treatments
- Actionable mutations: Identifies genetic changes in tumour cells that can be targeted with specific therapies.
- Treatment response predictors: Provides information to guide precision oncology treatment decisions.
NextGen GeneCore Paradigm – PDL1 and HRD: Who Needs It and Why It's Done
What Symptoms May Call for a NextGen GeneCore Paradigm – PDL1 and HRD?
This test is not ordered based on specific symptoms but is recommended after a cancer diagnosis. The decision to order this test depends on your cancer type, stage, and characteristics rather than initial symptoms:
- Already diagnosed with solid tumours where targeted therapies are available
- Cancer that has spread or returned after initial treatment
- Need for personalised treatment planning beyond standard chemotherapy.
- Consideration for immunotherapy or PARP inhibitor treatments
Who Should Get a NextGen GeneCore Paradigm – PDL1 and HRD?
This test is recommended for patients with specific types of cancer where treatments targeting PD-L1 and HRD pathways have proven effective:
- Ovarian cancer patients: Particularly those with high-grade serous ovarian cancer
- Triple-negative breast cancer patients: Where targeted therapies may be beneficial
- Non-small cell lung cancer patients: To determine immunotherapy eligibility
- Metastatic prostate cancer patients: For targeted treatment options
- Pancreatic cancer patients: To identify treatment vulnerabilities
- Other solid tumours: As determined by your oncologist based on clinical evidence
Why Is a NextGen GeneCore Paradigm – PDL1 and HRD Done?
This test is performed to predict how your tumour will respond to specific treatments, allowing your doctor to select personalised therapy with the highest chance of success while avoiding ineffective treatments and their side effects.
Importance of a NextGen GeneCore Paradigm – PDL1 and HRD
The GeneCore Paradigm – PDL1 and HRD test marks a turning point in modern precision cancer care. By identifying specific vulnerabilities in your tumour, such as high PD-L1 expression or HRD status, doctors can prescribe powerful targeted therapies or immunotherapies that are most likely to work for your individual case.
The test significantly improves treatment outcomes, as patients receiving biomarker-matched therapy often experience better responses and improved survival rates compared to standard treatments. It also helps avoid unnecessary toxicity and costs by ensuring expensive, potent drugs are given only to patients who will benefit most, protecting others from potential side effects, health risks, and financial burdens.
NextGen GeneCore Paradigm – PDL1 and HRD Booking & Reports – Metropolis Healthcare India
How to Book a NextGen GeneCore Paradigm – PDL1 and HRD?
- Simple Online Booking
Booking can be done through the Metropolis Healthcare App or website. Select the 'NextGen GeneCore Paradigm – PDL1 and HRD', choose a convenient time slot, and visit the nearest Metropolis Lab.
- Sample Tracking Updates
Stay informed at every step. From collection to testing, you can track your sample directly through the Metropolis Healthcare website.
- Accurate Laboratory Testing
Your sample is processed at our NABL & CAP accredited laboratories, where expert technicians ensure accurate results.
- Quick & Easy Reports
Receive your test reports promptly via email, WhatsApp, or by downloading them directly from the Metropolis Healthcare website or app.
Is Home Sample Collection for NextGen GeneCore Paradigm – PDL1 and HRD Available Near You?
No, home sample collection is not applicable for the GeneCore Paradigm – PDL1 and HRD. This test requires tumour tissue samples that are typically collected during medical procedures, like biopsies or surgeries, which must be performed in clinical settings. However, Metropolis Healthcare provides convenient sample processing services through our extensive network of over 10,000+ touchpoints across India.
How Long Does It Take to Get a NextGen GeneCore Paradigm – PDL1 and HRD Report?
Reports are usually available within 25 days once the sample reaches the pathology lab.
Note: Reporting time may vary depending on your location.
Where Can I See or Get NextGen GeneCore Paradigm – PDL1 and HRD Results?
Test results from Metropolis Healthcare can be accessed through multiple convenient channels. You can log in to the Metropolis website using your credentials or use the Metropolis Healthcare App to view and download your reports. Additionally, test reports are sent via email or WhatsApp, and you also have the option to collect a physical copy directly from the lab.
Interpreting NextGen GeneCore Paradigm – PDL1 and HRD Results
What Your NextGen GeneCore Paradigm – PDL1 and HRD Results May Indicate
The following table guides understanding of your test results, though your oncologist will interpret these findings in the context of your specific cancer type and overall health:
|
Parameter |
Result Type |
Positive/High Results |
Negative/Low Results |
|
PD-L1 Expression |
Percentage score (TPS) |
High expression suggests a good response to immunotherapy treatments. |
Low expression indicates immunotherapy may be less effective. |
|
HRD Status |
Positive/Negative |
HRD-positive indicates vulnerability to PARP inhibitor treatments. |
HRD-negative suggests DNA repair pathways are functioning normally. |
|
553 Actionable Mutations |
Present/Absent |
Specific mutations were detected that can be targeted with available therapies. |
No targetable mutations identified with current treatments. |
Conditions That May Affect NextGen GeneCore Paradigm – PDL1 and HRD Accuracy
Several factors can influence the accuracy of your test results and should be discussed with your healthcare team:
- Tissue sample quality: Inadequate or degraded tissue samples may affect test reliability.
- Tumour heterogeneity: Different areas of the same tumour may have varying characteristics.
- Previous treatments: Prior chemotherapy or radiation may alter tumour biology.
- Sample handling and storage: Improper tissue preservation can impact genetic analysis.
- Technical limitations: Some genetic alterations may be below detection thresholds.
- Contamination: Normal tissue contamination can dilute tumour-specific signals.
How Is a NextGen GeneCore Paradigm – PDL1 and HRD Done?
The test involves several carefully coordinated steps to ensure accurate analysis of your tumour tissue:
- Tissue collection: A biopsy or surgical sample is obtained by your doctor during a medical procedure.
- Sample preparation: The tissue is preserved in formalin and embedded in paraffin wax blocks.
- Quality assessment: Laboratory specialists evaluate tissue quality and tumour content.
- DNA/RNA extraction: Genetic material is carefully extracted from the tumour cells.
- Next-generation sequencing: Advanced sequencing technology analyses multiple genes simultaneously.
- Bioinformatics analysis: Sophisticated computer algorithms interpret the genetic data.
- Report generation: Results are compiled into a comprehensive report for your oncologist.
How Should You Prepare for a NextGen GeneCore Paradigm – PDL1 and HRD?
Preparation for this test focuses on the tissue collection procedure rather than the laboratory analysis itself:
- No fasting required: Your eating and drinking habits do not affect the tissue analysis.
- Continue medications: Unless specifically instructed otherwise by your doctor for the biopsy procedure.
- Provide a complete medical history: Share all relevant information about your cancer diagnosis and treatments.
- Bring histopathology reports: Previous tissue analysis reports help guide the testing process.
- Follow biopsy instructions: If tissue collection is needed, follow your doctor's specific preparation guidelines.
Diseases that the NextGen GeneCore Paradigm – PDL1 and HRD Can Help Detect
This test helps characterise various solid tumours and guide treatment decisions for several cancer types:
- Ovarian cancer: Particularly high-grade serous ovarian carcinoma
- Breast cancer: Including triple-negative and BRCA-associated cancers
- Lung cancer: Non-small cell lung cancer requiring immunotherapy assessment
- Prostate cancer: Advanced or metastatic prostate cancer
- Pancreatic cancer: Adenocarcinoma with potential targeted therapy options
- Kidney disorders related to cancer: Renal cell carcinoma
- Oesophageal cancer: Advanced oesophageal adenocarcinoma or squamous cell carcinoma
NextGen GeneCore Paradigm – PDL1 and HRD/Packages that You Can Book With Metropolis Healthcare
The following table shows related tests that complement comprehensive cancer care and treatment planning:
|
Test/Package Name |
Purpose/Highlights |
|
Measures overall genetic changes in tumours to predict immunotherapy response |
|
|
An immunohistochemistry test specifically for PD-L1 protein expression |
|
|
Detects DNA mismatch repair deficiency for targeted treatment options |
|
|
Identifies hereditary breast and ovarian cancer gene mutations |
Frequently asked questions
Find quick answers to the most common questions about health tests, bookings, and reports.
Regular exercise, a balanced diet, avoiding smoking, maintaining a healthy weight, and managing stress all help reduce heart disease risk.
Common signs include irritability, trouble sleeping, headaches, difficulty concentrating, and muscle tension.
Ratings & Reviews
We're satisfying our customers every day since 1980.
Choose precision On time, every time!
- 98% on time collections with a 60 minutes promise
- Real-time tracking of phlebotomist arrival and report generation
- Fully digital report delivery—view from mobile or desktop instantly
- Continuous monitoring of turnaround times to ensure accuracy and speed
- Dedicated support team to resolve any delays or queries quickly
Why Metropolis Healthcare?
Metropolis has been present for over 40 years in the market.
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
0
Years of experience
170+
Advanced Labs
Trusted by
Leading Doctors & Hospitals
2,000+
Scientific Officers
Proficiency Testing
for Accurate Reports
Latest Blogs & News
Stay informed with our expert insights and updates.
About Us
Metropolis Healthcare is a leading diagnostic service provider in India. We are a team of dedicated professionals committed to ensuring you and your family receive the most accurate and timely healthcare solutions. We believe in making health care accessible, affordable and evidence-based. Our expert panel are equipped with the latest technology and manned by a certified team of over 4000+ technicians.
In diagnostic services, we have more than three decades of experience servicing diverse stakeholders health advantage packages for men, women and seniors, genetic fitness & corporation in over 650+ tests like Oncology, Neurology, Gynaecology, Haematology, and many more. Our diagnostic services are located in leading doctors and clinics and serve over 15+ cities in India.